STOCK TITAN

Acurx Pharmaceuticals Inc - ACXP STOCK NEWS

Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.

Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company pioneering novel antibiotics for resistant Gram-positive infections. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.

Access timely reports on clinical trial developments, including Phase 3 preparations for ibezapolstat targeting C. difficile infections. Stay informed about patent grants, research collaborations, and financial disclosures that demonstrate ACXP's commitment to addressing antimicrobial resistance through targeted DNA polymerase IIIC inhibition technology.

Our curated collection features press releases detailing milestone achievements, peer-reviewed study publications, and strategic partnership announcements. All content is verified for accuracy and relevance to support informed decision-making in the evolving antibiotic development landscape.

Bookmark this page for direct access to Acurx's latest progress in creating narrow-spectrum therapies that combat priority pathogens while preserving microbiome balance – a critical differentiator in modern infectious disease treatment.

Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP) announced its Q1 2024 financial and operational results, highlighting significant progress in its clinical trials and business operations.

Key achievements include positive data from the Phase 2b trial of ibezapolstat, which showed superior results over vancomycin for treating CDI, with a 94% eradication rate of C. difficile by Day 3. The FDA has agreed on the Phase 3 program and NDA filing pathway. The European Medicines Agency designated Acurx as an SME, providing fee reductions and support.

Financially, Acurx ended Q1 2024 with $8.9 million in cash, up from $7.5 million at the end of 2023. The company reported a net loss of $4.4 million, driven by increased R&D and G&A expenses. 1,121,793 shares were sold under ATM financing, raising $4.4 million.

Further data and presentations are anticipated throughout 2024 at several scientific conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
-
Rhea-AI Summary

Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals announces the presentation of Ibezapolostat Phase 2 clinical trial results at the upcoming ESCMID 2024 Scientific Conference. The trial focused on patients with C. difficile infection, with additional analyses of clinical and microbiological data. The oral presentation by Kevin Garey, a prominent figure in microbiology, will compare Ibezapolostat with Vancomycin in treating CDI. The poster presentation will showcase the antibacterial activity of Ibezapolostat against antimicrobial-resistant strains of C. difficile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) will discuss its first quarter 2024 financial results on May 15, 2024, along with a business update. The company is focused on developing new antibiotics for difficult-to-treat bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (ACXP) will be presenting at The 14th Annual LD Micro Invitational on April 8th-9th, 2024. The event will showcase 80 companies with Acurx scheduled to present on April 8th at 2:30 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (ACXP) reported positive Phase 2b clinical trial results for ibezapolstat in treating C. difficile infection. The trial demonstrated a high clinical cure rate of 96%, outperforming vancomycin. The company submitted data to the FDA for an End of Phase 2 Meeting and received SME designation from the EMA. Despite positive clinical data, financial results showed a decrease in cash position, increased R&D and G&A expenses, and a net loss for the quarter and year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.78%
Tags
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (ACXP) to Release Q4 and Full Year 2023 Financial Results on March 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announces FDA EOP2 meeting granted to discuss Phase 3 development plan for ibezapolstat in treating CDI. The Company submitted pre-meeting Briefing Document and received SME designation from EMA for EU Marketing Authorization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
-
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced positive extended clinical cure data for ibezapolstat (IBZ) from the Phase 2b trial in patients with CDI. 100% of IBZ patients experienced no recurrence of infection, and further analyses on bile acid metabolism and pharmacokinetic data are forthcoming. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation. The company is preparing for meetings with regulatory agencies and advancement to international Phase 3 clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
Rhea-AI Summary
Acurx Pharmaceuticals, Inc. announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference to discuss the development of small molecule antibiotics for bacterial infections. The conference will take place from January 30th to February 1st at the Ceasars Atlantic City Hotel & Casino. Interested parties can register to attend the presentation on January 31st and February 1st.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
conferences
Acurx Pharmaceuticals Inc

Nasdaq:ACXP

ACXP Rankings

ACXP Stock Data

8.22M
19.47M
11.67%
9.8%
2.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
STATEN ISLAND